Eisai wins reimbursement for Zebinix in France, just Italy to go
This article was originally published in Scrip
Executive Summary
Eisai's epilepsy drug, Zebinix (eslicarbazepine acetate) has won reimbursement in France as an adjunct therapy for adults with partial onset seizures. This means that the firm has only to seek reimbursement in Italy, where a new submission is underway to try and secure a better price, Eisai told Scrip.